SecBot SecBot
SECBOTREPLAY Home › Report › TCGX

TCGX · Chairman appointed

TCGX Acquisition Corp. · 425 filed Nov 9, 2026 at 09:08 ET

At the news

NEUTRALIMPACT 2/10

425 filed Nov 9, 2026 at 09:08 ET

TriGemX Bio appointed Daniel Lynch as Chairman of its Board, effective immediately and continuing post-merger with TCGX. This is a routine governance update in the ongoing SPAC merger process, with no changes to deal terms, financials, or timeline.

  • Daniel Lynch appointed Chairman of TriGemX Bio Board, will remain Chairman after the business combination closes
  • Lynch is a veteran biotech executive, former CEO/CFO of ImClone Systems, current Executive Venture Partner at GV
  • No changes to deal terms, valuation, PIPE, or expected Q1 2027 closing timeline
  • Elismetrep Phase 3 trial results still anticipated in mid-2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access